Form 4: Pulmonx Chief Commercial Officer Sells Shares to Cover Tax Obligations
Insider Transaction Report
Pulmonx Corporation's Chief Commercial Officer, Geoffrey Beran Rose, reported the sale of 6,947 shares of common stock on June 2, 2025, to satisfy tax withholding requirements related to the vesting of Restricted Stock Units.
Summary
- Geoffrey Beran Rose, Chief Commercial Officer of Pulmonx Corp (LUNG), reported transactions on June 2, 2025.
- A total of 6,947 shares of Pulmonx Common Stock were disposed of directly by Mr. Rose.
- The sales were executed at prices ranging from $3.13 to $3.14 per share.
- These sales were specifically conducted to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
- The RSUs were granted on various dates: June 1, 2021; March 1, 2022; March 1, 2023; March 1, 2024; and March 3, 2025.
- Following these transactions, Mr. Rose beneficially owns 386,331 shares of Pulmonx Common Stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the reported transactions are routine, non-discretionary sales to cover tax obligations arising from RSU vesting, rather than a strategic divestment or a reflection of management's view on the company's prospects.
Future Outlook
This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Management Comments
- The shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs).
Industry Context
Insider sales for tax withholding purposes are a routine occurrence in publicly traded companies, particularly for executives receiving equity compensation like Restricted Stock Units. This type of transaction is common across various industries as a mechanism for employees to manage tax liabilities arising from vested equity awards.
Stakeholder Impact
- Shareholders: The sale represents a minor dilution of insider ownership, but it is a routine event for tax purposes and not indicative of a change in confidence. The total number of shares sold is a small fraction of the company's outstanding shares.
- Employees: The transaction highlights the common practice of equity compensation and the associated tax implications for employees receiving such awards.
Key Dates
| Date | Description |
|---|---|
| 2021-06-01 | Grant date for a portion of the Restricted Stock Units (RSUs) that vested. |
| 2022-03-01 | Grant date for a portion of the Restricted Stock Units (RSUs) that vested. |
| 2023-03-01 | Grant date for a portion of the Restricted Stock Units (RSUs) that vested. |
| 2024-03-01 | Grant date for a portion of the Restricted Stock Units (RSUs) that vested. |
| 2025-03-03 | Grant date for a portion of the Restricted Stock Units (RSUs) that vested. |
| 2025-06-02 | Date of reported stock transactions (sales to cover tax withholding). |
| 2025-06-04 | Date the Form 4 was signed by the Attorney-in-Fact for the Reporting Person. |
Keywords
Pulmonx Corp, LUNG, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Geoffrey Beran Rose, Chief Commercial Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.